Literature DB >> 9596727

Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans.

J W Murphy1, F Schafer, A Casadevall, A Adesina.   

Abstract

Mice immunized with two different cryptococcal antigen preparations, one a soluble culture filtrate antigen (CneF) in complete Freund's adjuvant (CFA) and the other heat-killed Cryptococcus neoformans cells (HKC), develop two different profiles of activated T cells. CneF-CFA induces CD4+ T cells responsible for delayed-type hypersensitivity (DTH) reactivity and for amplification of the anticryptococcal DTH response, whereas HKC induce CD4+ and CD8+ T cells involved in anticryptococcal DTH reactivity and activated T cells which directly kill C. neoformans cells. The main purpose of this study was to assess the level of protection afforded by each of the two different T-cell profiles against challenge with viable C. neoformans cells, thereby identifying which activated T-cell profile provides better protection. CBA/J mice immunized with CneF-CFA had significantly better protective responses, based on better clearance of C. neoformans from tissues, on longer survival times, and on fewer and smaller lesions in the brain, than HKC-immunized mice or control mice similarly infected with C. neoformans. Both immunization protocols induced an anticryptococcal DTH response, but neither induced serum antibodies to glucuronoxylmannan, so the protection observed in the CneF-CFA immunized mice was due to the activated T-cell profile induced by that protocol. HKC-immunized mice, which displayed no greater protection than controls, did not have the amplifier cells. Based on our findings, we propose that the protective anticryptococcal T cells are the CD4+ T cells which have been shown to be responsible for DTH reactivity and/or the CD4+ T cells which amplify the DTH response and which have been previously shown to produce high levels of gamma interferon and interleukin 2. Our results imply that there are protective and nonprotective cell-mediated immune responses and highlight the complexity of the immune response to C. neoformans antigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596727      PMCID: PMC108249          DOI: 10.1128/IAI.66.6.2632-2639.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Active immunization against Cryptococcus neoformans.

Authors:  H H GADEBUSCH
Journal:  J Infect Dis       Date:  1958 May-Jun       Impact factor: 5.226

2.  Studies of the capsular substance of Torula histolytica and the immunologic properties of Torula cells.

Authors:  A M KLIGMAN
Journal:  J Immunol       Date:  1947-12       Impact factor: 5.422

3.  Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.

Authors:  A Casadevall; J Mukherjee; S J Devi; R Schneerson; J B Robbins; M D Scharff
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

4.  Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response.

Authors:  J W Murphy
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

5.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

Authors:  A Casadevall; J Mukherjee; M D Scharff
Journal:  J Immunol Methods       Date:  1992-09-18       Impact factor: 2.303

6.  Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes.

Authors:  S M Muth; J W Murphy
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

7.  Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice.

Authors:  S M Muth; J W Murphy
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

8.  Resistance to Cryptococcus neoformans is associated with an inflammatory response to Toxoplasma gondii in the central nervous system of mice.

Authors:  K M Aguirre; P C Sayles; G W Gibson; L L Johnson
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

9.  Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans.

Authors:  I E Flesch; G Schwamberger; S H Kaufmann
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

10.  T cell-dependent activation of macrophages and enhancement of their phagocytic activity in the lungs of mice inoculated with heat-killed Cryptococcus neoformans: involvement of IFN-gamma and its protective effect against cryptococcal infection.

Authors:  K Kawakami; S Kohno; J Kadota; M Tohyama; K Teruya; N Kudeken; A Saito; K Hara
Journal:  Microbiol Immunol       Date:  1995       Impact factor: 1.955

View more
  24 in total

1.  Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.

Authors:  Rebecca Blackstock
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

2.  Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice.

Authors:  K L Buchanan; H A Doyle
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions.

Authors:  Débora L Oliveira; Célio G Freire-de-Lima; Joshua D Nosanchuk; Arturo Casadevall; Marcio L Rodrigues; Leonardo Nimrichter
Journal:  Infect Immun       Date:  2010-02-09       Impact factor: 3.441

4.  Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection.

Authors:  B C Fries; C P Taborda; E Serfass; A Casadevall
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

5.  Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans.

Authors:  D Pietrella; R Cherniak; C Strappini; S Perito; P Mosci; F Bistoni; A Vecchiarelli
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

6.  Differences in components at delayed-type hypersensitivity reaction sites in mice immunized with either a protective or a nonprotective immunogen of Cryptococcus neoformans.

Authors:  Kasie L Nichols; Sean K Bauman; Fredda B Schafer; Juneann W Murphy
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

7.  Age-related resistance of C57BL/6 mice to Cryptococcus neoformans is dependent on maturation of NKT cells.

Authors:  Rebecca Blackstock; Juneann W Murphy
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses.

Authors:  Chao Huang; Shu-Hua Nong; Michael K Mansour; Charles A Specht; Stuart M Levitz
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Protective efficacy of antigenic fractions in mouse models of cryptococcosis.

Authors:  Michael K Mansour; Lauren E Yauch; James B Rottman; Stuart M Levitz
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Sailatha Ravi; Sandra Macias; Mattie L Young; Michal A Olszewski; Chad Steele; Floyd L Wormley
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.